[com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1790]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1779]], com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1787]]][com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=91954]], camposKey:1350-9047 2025-08-01 Neutralization of acyl CoA binding protein (ACBP) for the experimental treatment of osteoarthritis14841498, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=91955]], camposKey:0027-8424 2025-07-15 Acyl-CoA-binding protein as a driver of pathological aging00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=91956]], camposKey:2666-3791 2025-07-15 Neutralization of acyl coenzyme A binding protein for the experimental prevention and treatment of hepatocellular carcinoma00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=88629]], camposKey:2522-5812 2024-12-01 Pathogenic role of acyl coenzyme A binding protein (ACBP) in Cushing¿s syndrome22812299, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=86883]], camposKey:1661-6596 2024-08-01 Obesity-Associated Colorectal Cancer00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=88631]], camposKey:1350-9047 2024-01-01 ACBP/DBI neutralization for the experimental treatment of fatty liver disease00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=87744]], camposKey:1946-6234 2024-01-01 Acyl-CoA binding protein for the experimental treatment of anorexia00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=87745]], camposKey:2041-4889 2024-01-01 Inhibition of acyl-CoA binding protein (ACBP) by means of a GABAAR¿2-derived peptide00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=88630]], camposKey:1554-8627 2024-01-01 Lysosomal damage due to cholesterol accumulation triggers immunogenic cell death00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79883]], camposKey:1476-4598 2023-12-01 Protein regulator of cytokinesis 1: a potential oncogenic driver00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79884]], camposKey:2041-4889 2023-11-01 3,4-dimethoxychalcone induces autophagy and reduces neointimal hyperplasia and aortic lesions in mouse models of atherosclerosis00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79885]], camposKey:1474-9718 2023-09-01 Acyl coenzyme A binding protein (ACBP): An aging- and disease-relevant ¿autophagy checkpoint¿00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79886]], camposKey:1520-6106 2023-06-01 Full-Spectrum CARS Microscopy of Cells and Tissues with Ultrashort White-Light Continuum Pulses47334745, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=75300]], camposKey:1661-6596 2023-04-01 Involvement of Bcl-2 Family Proteins in Tetraploidization-Related Senescence00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79888]], camposKey:1554-8627 2023-01-01 Cardio-, hepato- and pneumoprotective effects of autophagy checkpoint inhibition by targeting DBI/ACBP16041606, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79887]], camposKey:1474-9718 2023-01-01 High plasma concentrations of acyl-coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=73595]], camposKey:0027-8424 2022-10-11 ACBP/DBI protein neutralization confers autophagy-dependent organ protection through inhibition of cell loss, inflammation, and fibrosis00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79889]], camposKey:2041-4889 2022-05-01 Correction: An obesogenic feedforward loop involving PPAR¿, acyl-CoA binding protein and GABA receptor (Cell Death & Disease, (2022), 13, 4, (356), 10.1038/s41419-022-04834-5)00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79890]], camposKey:2041-4889 2022-04-01 An obesogenic feedforward loop involving PPAR¿, acyl-CoA binding protein and GABAA receptor00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79891]], camposKey:2666-1667 2022-03-18 Immunization of mice with the self-peptide ACBP coupled to keyhole limpet hemocyanin00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=73596]], camposKey:2041-4889 2021-11-01 Paradoxical implication of BAX/BAK in the persistence of tetraploid cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79892]], camposKey:2041-4889 2021-06-01 Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79893]], camposKey:2162-3945 2020-01-01 Antibody-mediated neutralization of ACBP/DBI has anorexigenic and lipolytic effects116119, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79894]], camposKey:0270-9139 2019-08-01 Protective Role of Hepatocyte Cyclooxygenase-2 Expression Against Liver Ischemia¿Reperfusion Injury in Mice650665, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79895]], camposKey:0955-2863 2018-08-01 Disruption of tumor necrosis factor alpha receptor 1 signaling accelerates NAFLD progression in mice upon a high-fat diet1727, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79896]], camposKey:0925-4439 2018-02-01 PGE2 induces apoptosis of hepatic stellate cells and attenuates liver fibrosis in mice by downregulating miR-23a-5p and miR-28a-5p325337, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79897]], camposKey:0041-008X 2017-01-15 Benznidazole, the trypanocidal drug used for Chagas disease, induces hepatic NRF2 activation and attenuates the inflammatory response in a murine model of sepsis1222, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79898]], camposKey:0925-4439 2016-09-01 Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice17101723, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79899]], camposKey:2211-1247 2016-05-03 Alternative Splicing of Neuronal Differentiation Factor TRF2 Regulated by HNRNPH1/H2926934, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79900]], camposKey:0012-1797 2015-05-01 Hepatic cyclooxygenase-2 expression protects against diet-induced steatosis, obesity, and insulin resistance15221531, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79901]], camposKey:0270-7306 2015-01-01 Regulation of microRNA 183 by cyclooxygenase 2 in liver is DEAD-box helicase p68 (DDX5) dependent: Role in insulin signaling25542567, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79902]], camposKey:1357-2725 2013-09-11 Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma25012511, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79903]], camposKey:0898-6568 2013-01-01 Distinct and specific roles of AKT1 and AKT2 in androgen-sensitive and androgen-independent prostate cancer cells15861597, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79904]], camposKey:1932-6203 2012-11-30 Cyclooxygenase-2 Is a Target of MicroRNA-16 in Human Hepatoma Cells00, com.sigma.fs3.argos.domain.gpc.GpcArticlesRev[id=com.sigma.fs3.argos.domain.gpc.GpcArticlesRevPK[ifcactivitat=ARE, ifccomptador=79905]], camposKey:0143-3334 2012-11-01 EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway11691177][CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=34287]},camposKey: 67 75 A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet 978-1-0716-3694-7Liver Carcinogenesis 1 2024-01-01 Springer, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=34280]},camposKey: A Mouse Model of Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma Induced by Western Diet and Carbon Tetrachloride 978-1-0716-3694-7Liver Carcinogenesis 1 2024-01-01 Springer, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=34290]},camposKey: 199 209 Biomarker Identification in Liver Cancers Using Desorption Electrospray Ionization Mass Spectrometry (DESI-MS) Imaging: An Approach for Spatially Resolved Metabolomics 978-1-0716-3694-7Liver Carcinogenesis 1 2024-01-01 Springer, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=34288]},camposKey: 109 128 Isolation of Primary Mouse Hepatocytes and Non-Parenchymal Cells from a Liver with Precancerous Lesions 978-1-0716-3694-7Liver Carcinogenesis 1 2024-01-01 Springer, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=34279]},camposKey: Orthotopic Model of Hepatocellular Carcinoma in Mice 978-1-0716-3694-7Liver Carcinogenesis 1 2024-01-01 Springer, CapitolsLlib{id=com.sigma.fs3.argos.domain.gpc.GpcCapitolsLlibPK[ifcactivitat=CAP, ifccomptador=34289]},camposKey: 189 198 Targeted Analysis of Glycerophospholipids and Mono-, Di-, or Tri-Acylglycerides in Liver Cancer 978-1-0716-3694-7Liver Carcinogenesis 1 2024-01-01 Springer][com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=2178]], com.sigma.fs3.argos.domain.gpc.ColabRevistes[id=com.sigma.fs3.argos.domain.gpc.GpcColabRevistesPK[ifcactivitat=COL, ifccomptador=2173]]][][com.sigma.fs3.argos.domain.gpc.AltresActivPers[id=com.sigma.fs3.argos.domain.gpc.GpcAltresActivPersPK[ifcactivitat=AAP, ifccomptador=1924]]][][][][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=65886]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=65585]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=65583]]][com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=65886]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=65585]], com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBeca[id=com.sigma.fs3.argos.domain.gpc.GpcAltresAjutsBecaPK[ifcactivitat=AAB, ifccomptador=65583]]][][][][][][][][][][][com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@4168c001, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@2f0e4bc5, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@435b2632, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@f3c3a7d, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@8d38b53, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@55deb9ef, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@4f2e6fd0, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@21af4b9a, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@35b2c5ef, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@15031377, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@29efbee8, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@72c7d3d4, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@51f9edde, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@5cecd43d, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@8a029b6, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@44351205, com.sigma.investigacion.cawdos.utilidades.CongresoYSusAsociaciones@5a3c9040][][com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ConvenisPPC@633c3e][com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=4049]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=4048]]][com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=4049]], com.sigma.fs3.argos.domain.gpc.GpcCursosSeminaris[id=com.sigma.fs3.argos.domain.gpc.GpcCursosSeminarisPK[ifcactivitat=CUR, ifccomptador=4048]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=62283]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=62279]]][com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=62283]], com.sigma.fs3.argos.domain.gpc.EstadesFora[id=com.sigma.fs3.argos.domain.commons.ArgosPK[act=ESF, cont=62279]]][][com.sigma.fs3.argos.domain.gpc.GpcPatents[id=com.sigma.fs3.argos.domain.gpc.GpcPatentsPK[ifcactivitat=PAT, ifccomptador=1553]]][][com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c57ad], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@56f250], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c1ed2], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c2494], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c1ed1], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c1ece], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c1ecc], com.sigma.investigacion.cawdos.entities.ayudaInvestigacion.ProjectesPPC[id=com.sigma.fs3.argos.domain.gpc.ayudasrecerca.ProjectesPPCId@5c1ecd]][][][][][][][][]
